nach oben

Current Geriatrics Reports

Erschienen in:

01.06.2012 | Biomarkers in the Classification of Biological Health and Disease Aging (Y Shen, Section Editor)

Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases

verfasst von: Xiao-Xin Yan, Andreas Jeromin

Erschienen in: Current Geriatrics Reports | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

The expected lifespan of the world’s human population grows rapidly thanks to the great advance in modern medicine. While more and more body system diseases become treatable and curable, age-related neurodegenerative diseases remain poorly understood mechanistically, and are desperately in need of preventive and therapeutic interventions. Biomarker development consists of a key part of concerted efforts in combating neurodegenerative diseases. In many chronic neurodegenerative conditions, neuronal damage/death occurs long before the onset of disease symptoms, and abnormal proteolysis may either play an active role or be an accompanying event of neuronal injury. Increased spectrin cleavage yielding elevated spectrin breakdown products (SBDPs) by calcium-sensitive proteases such as calpain and caspases has been established in conditions associated with acute neuronal damage such as traumatic brain injury (TBI). In this article, we review literature regarding spectrin expression and metabolism in the brain, and propose a potential use of SBDPs as biomarkers for neurodegenerative diseases such as Alzheimer’s disease.

Marchesi VT, Steers Jr E. Selective solubilization of a protein component of the red cell membrane. Science. 1968;159:203–4.PubMedCrossRef

Goodman SR, Zagon IS, Whitfield CF, et al. A spectrin-like protein from mouse brain membranes: immunological and structural correlations with erythrocyte spectrin. Cell Motil. 1983;3:635–47.PubMedCrossRef

Bennett V, Lambert S. The spectrin skeleton: from red cells to brain. J Clin Invest. 1991;87:1483–9.PubMedCrossRef

Baines AJ. Evolution of spectrin function in cytoskeletal and membrane networks. Biochem Soc Trans. 2009;37:796–803.PubMedCrossRef

Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet. 2006;38:184–90.PubMedCrossRef

Lynch G, Baudry M. Brain spectrin, calpain and long-term changes in synaptic efficacy. Brain Res Bull. 1987;18:809–15.PubMedCrossRef

Czogalla A, Sikorski AF. Spectrin and calpain: a 'target' and a 'sniper' in the pathology of neuronal cells. Cell Mol Life Sci. 2005;62:1913–24.PubMedCrossRef

Pineda JA, Lewis SB, Valadka AB, et al. Clinical significance of alphaII-spectrin breakdown products in cerebrospinal fluid after severe traumatic brain injury. J Neurotrauma. 2007;24:354–66.PubMedCrossRef

Weiss ES, Wang KK, Allen JG, et al. Alpha II-spectrin breakdown products serve as novel markers of brain injury severity in a canine model of hypothermic circulatory arrest. Ann Thorac Surg. 2009;88:543–50.PubMedCrossRef

10.

Zhang Z, Larner SF, Liu MC, et al. Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis. 2009;14:1289–98.PubMedCrossRef

11.

Mondello S, Robicsek SA, Gabrielli A, et al. αII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma. 2010;27:1203–13.PubMedCrossRef

12.

Peterson C, Vanderklish P, Seubert P, et al. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors. Neurosci Lett. 1991;121:239–43.PubMedCrossRef

13.

Masliah E, Iimoto DS, Saitoh T, et al. Increased immunoreactivity of brain spectrin in Alzheimer disease: a marker for synapse loss? Brain Res. 1990;531:36–44.PubMedCrossRef

14.

Mangeat PH. Interaction of biological membranes with the cytoskeletal framework of living cells. Biol Cell. 1988;64:261–81.PubMedCrossRef

15.

Palek J, Lambert S. Genetics of the red cell membrane skeleton. Semin Hematol. 1990;27:290–332.PubMed

16.

Winkelmann JC, Forget BG. Erythroid and nonerythroid spectrins. Blood. 1993;81:3173–85.PubMed

17.

Delaunay J. The molecular basis of hereditary red cell membrane disorders. Blood Rev. 2007;21:1–20.PubMedCrossRef

18.

Gallagher PG. Update on the clinical spectrum and genetics of red blood cell membrane disorders. Curr Hematol Rep. 2004;3:85–91.PubMed

19.

Karinch AM, Zimmer WE, Goodman SR. The identification and sequence of the actin-binding domain of human red blood cell beta-spectrin. J Biol Chem. 1990;265:11833–40.PubMed

20.

Fowler V, Taylor DL. Spectrin plus band 4.1 cross-link actin. Regulation by micromolar calcium. J Cell Biol. 1980;85:361–76.PubMedCrossRef

21.

Davis JQ, Bennett V. Brain ankyrin. Purification of a 72,000 Mr spectrin-binding domain. J Biol Chem. 1984;259:1874–81.PubMed

22.

Coleman TR, Harris AS, Mische SM, et al. Beta spectrin bestows protein 4.1 sensitivity on spectrin-actin interactions. J Cell Biol. 1987;104:519–26.PubMedCrossRef

23.

Fowler VM, Bennett V. Erythrocyte membrane tropomyosin. Purification and properties. J Biol Chem. 1984;259:5978–89.PubMed

24.

Fowler VM. Tropomodulin: a cytoskeletal protein that binds to the end of erythrocyte tropomyosin and inhibits tropomyosin binding to actin. J Cell Biol. 1990;111:471–81.PubMedCrossRef

25.

Gardner K, Bennett V. Modulation of spectrin-actin assembly by erythrocyte adducin. Nature. 1987;328:359–62.PubMedCrossRef

26.

Morris CE. Mechanoprotection of the plasma membrane in neurons and other non-erythroid cells by the spectrin-based membrane skeleton. Cell Mol Biol Lett. 2001;6:703–20.PubMed

27.

Mastrangelo M, Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol. 2012;46:24–31.PubMedCrossRef

28.

Fukushima Y, Byers MG, Watkins PC, et al. Assignment of the gene for beta-spectrin (SPTB) to chromosome 14q23----q24.2 by in situ hybridization. Cytogenet Cell Genet. 1990;53:232–3.PubMedCrossRef

29.

Dhermy D, Galand C, Bournier O, et al. Hereditary spherocytosis with spectrin deficiency related to null mutations of the beta-spectrin gene. Blood Cells Mol Dis. 1998;24:251–61.PubMedCrossRef

30.

Gallagher PG, Petruzzi MJ, Weed SA, et al. Mutation of a highly conserved residue of betaI spectrin associated with fatal and near-fatal neonatal hemolytic anemia. J Clin Invest. 1997;99:267–77.PubMedCrossRef

31.

Stankewich MC, Tse WT, Peters LL, et al. A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles. Proc Natl Acad Sci U S A. 1998;95:14158–63.PubMedCrossRef

32.

Berghs S, Aggujaro D, Dirkx Jr R, et al. betaIV spectrin, a new spectrin localized at axon initial segments and nodes of ranvier in the central and peripheral nervous system. J Cell Biol. 2000;151:985–1002.PubMedCrossRef

33.

Stabach PR, Morrow JS. Identification and characterization of beta V spectrin, a mammalian ortholog of Drosophila beta H spectrin. J Biol Chem. 2000;275:21385–95.PubMedCrossRef

34.

Jiang X, Gillen S, Esposito I, et al. Reduced expression of the membrane skeleton protein beta1-spectrin (SPTBN1) is associated with worsened prognosis in pancreatic cancer. Histol Histopathol. 2010;25:1497–506.PubMed

35.

Bennett V, Davis J, Fowler WE. Brain spectrin, a membrane-associated protein related in structure and function to erythrocyte spectrin. Nature. 1982;299:126–31.PubMedCrossRef

36.

Bennett V, Healy J. Organizing the fluid membrane bilayer: diseases linked to spectrin and ankyrin. Trends Mol Med. 2008;4:28–36.CrossRef

37.

Goodman SR, Zimmer WE, Clark MB, et al. Brain spectrin: of mice and men. Brain Res Bull. 1995;36:593–606.PubMedCrossRef

38.

Zagon IS, Higbee R, Riederer BM, Goodman SR. Spectrin subtypes in mammalian brain: an immunoelectron microscopic study. J Neurosci. 1986;6:2977–86.PubMed

39.

Susuki K, Raphael AR, Ogawa Y, et al. Schwann cell spectrins modulate peripheral nerve myelination. Proc Natl Acad Sci U S A. 2011;108:8009–80014.PubMedCrossRef

40.

Koenig E, Kinsman S, Repasky E, Sultz L. Rapid mobility of motile varicosities and inclusions containing alpha-spectrin, actin, and calmodulin in regenerating axons in vitro. J Neurosci. 1985;5:715–29.PubMed

41.

Bloch RJ, Morrow JS. An unusual beta-spectrin associated with clustered acetylcholine receptors. J Cell Biol. 1989;8:481–93.CrossRef

42.

Sunderland WJ, Son YJ, Miner JH, et al. The presynaptic calcium channel is part of a transmembrane complex linking a synaptic laminin (alpha4beta2gamma1) with non-erythroid spectrin. J Neurosci. 2000;20:1009–19.PubMed

43.

Lacas-Gervais S, Guo J, Strenzke N, et al. BetaIVSigma1 spectrin stabilizes the nodes of Ranvier and axon initial segments. J Cell Biol. 2004;166:983–90.PubMedCrossRef

44.

Hülsmeier J, Pielage J, Rickert C, et al. Distinct functions of alpha-spectrin and beta-spectrin during axonal pathfinding. Development. 2007;134:713–22.PubMedCrossRef

45.

Yang Y, Ogawa Y, Hedstrom KL, Rasband MN. betaIV spectrin is recruited to axon initial segments and nodes of Ranvier by ankyrin G. J Cell Biol. 2007;176:509–19.PubMedCrossRef

46.

Voas MG, Lyons DA, Naylor SG, et al. alphaII-spectrin is essential for assembly of the nodes of Ranvier in myelinated axons. Curr Biol. 2007;7:562–8.CrossRef

47.

Puchkov D. Leshchyns'ka I, Nikonenko AG, et al.: NCAM/spectrin complex disassembly results in PSD perforation and postsynaptic endocytic zone formation. Cereb Cortex. 2011;21:2217–32.PubMedCrossRef

48.

Pielage J, Fetter RD, Davis GW. A postsynaptic spectrin scaffold defines active zone size, spacing, and efficacy at the Drosophila neuromuscular junction. J Cell Biol. 2006;175:491–503.PubMedCrossRef

49.

Ramser EM, Buck F, Schachner M, Tilling T. Binding of alphaII spectrin to 14-3-3beta is involved in NCAM-dependent neurite outgrowth. Mol Cell Neurosci. 2010;45:66–74.PubMedCrossRef

50.

Stankewich MC, Gwynn B, Ardito T, et al. Targeted deletion of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes. Proc Natl Acad Sci U S A. 2010;107:6022–7.PubMedCrossRef

51.

Westphal D, Sytnyk V, Schachner M. Leshchyns'ka I: Clustering of the neural cell adhesion molecule (NCAM) at the neuronal cell surface induces caspase-8- and -3-dependent changes of the spectrin meshwork required for NCAM-mediated neurite outgrowth. J Biol Chem. 2010;285:42046–57.PubMedCrossRef

52.

Gao Y, Perkins EM, Clarkson YL, et al. β-III spectrin is critical for development of Purkinje cell dendritic tree and spine morphogenesis. J Neurosci. 2011;31:16581–90.PubMedCrossRef

53.

Nestor MW, Cai X, Stone MR, et al. The actin binding domain of βI-spectrin regulates the morphological and functional dynamics of dendritic spines. PLoS. 2011;6:e16197.

54.

Lorenzo DN, Li MG, Mische SE, et al. Spectrin mutations that cause spinocerebellar ataxia type 5 impair axonal transport and induce neurodegeneration in Drosophila. J Cell Biol. 2010;189:143–58.PubMedCrossRef

55.

Perkins EM, Clarkson YL, Sabatier N, et al. Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans. J Neurosci. 2010;30:4857–67.PubMedCrossRef

56.

Nath R, Raser KJ, Stafford D, et al. Non-erythroid alpha-spectrin breakdown by calpain and interleukin 1 beta-converting-enzyme-like protease(s) in apoptotic cells: contributory roles of both protease families in neuronal apoptosis. Biochem J. 1996;319:683–90.PubMed

57.

Hsu YJ, Zimmer WE, Goodman SR. Erythrocyte spectrin’s chimeric E2/E3 ubiquitin conjugating/ligating activity. Cell Mol Biol (Noisy-le-grand). 2005;51:187–93.

58.

Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII- and betaII-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem. 1998;273:22490–7.PubMedCrossRef

59.

Zhao X, Newcomb JK, Pike BR, et al. Novel characteristics of glutamate-induced cell death in primary septohippocampal cultures: relationship to calpain and caspase-3 protease activation. J Cereb Blood Flow Metab. 2000;20:550–62.PubMedCrossRef

60.

Newcomb-Fernandez JK, Zhao X, Pike BR, et al. Concurrent assessment of calpain and caspase-3 activation after oxygen-glucose deprivation in primary septo-hippocampal cultures. J Cereb Blood Flow Metab. 2001;21:1281–94.PubMedCrossRef

61.

Pike BR, Flint J, Dave JR, et al. Accumulation of calpain and caspase-3 proteolytic fragments of brain-derived alphaII-spectrin in cerebral spinal fluid after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab. 2004;24:98–106.PubMedCrossRef

62.

Gold MS, Kobeissy FH, Wang KK, et al. Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry. 2009;66:118–27.PubMedCrossRef

63.

Vanderklish PW, Bahr BA. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol. 2000;81:323–239.PubMedCrossRef

64.

Bahr BA, Tiriveedhi S, Park GY, Lynch G. Induction of calpain-mediated spectrin fragments by pathogenic treatments in long-term hippocampal slices. J Pharmacol Exp Ther. 1995;273:902–8.PubMed

65.

Seubert P, Larson J, Oliver M, et al. Stimulation of NMDA receptors induces proteolysis of spectrin in hippocampus. Brain Res. 1988;460:189–94.PubMedCrossRef

66.

Siman R, Noszek JC, Kegerise C. Calpain I activation is specifically related to excitatory amino acid induction of hippocampal damage. J Neurosci. 1989;9:1579–90.PubMed

67.

Bi X, Chang V, Siman R, et al. Regional distribution and time-course of calpain activation following kainate-induced seizure activity in adult rat brain. Brain Res. 1996;726:98–108.PubMedCrossRef

68.

Tamada Y, Nakajima E, Nakajima T, et al. Proteolysis of neuronal cytoskeletal proteins by calpain contributes to rat retinal cell death induced by hypoxia. Brain Res. 2005;1050:148–55.PubMedCrossRef

69.

Huang W, Fileta J, Rawe I, Qu J, Grosskreutz CL. Calpain activation in experimental glaucoma. Invest Ophthalmol Vis Sci. 2010;51:3049–54.PubMedCrossRef

70.

Hwang IK, Yoo KY, Kim DW, et al. AlphaII-spectrin breakdown product increases in principal cells in the gerbil main olfactory bulb following transient ischemia. Neurosci Lett. 2008;435:251–6.PubMedCrossRef

71.

Farkas O, Polgár B, Szekeres-Barthó J, et al. Spectrin breakdown products in the cerebrospinal fluid in severe head injury–preliminary observations. Acta Neurochir (Wien). 2005;147:855–61.CrossRef

72.

Brophy GM, Pineda JA, Papa L, et al. alphaII-Spectrin breakdown product cerebrospinal fluid exposure metrics suggest differences in cellular injury mechanisms after severe traumatic brain injury. J Neurotrauma. 2009;26:471–9.PubMedCrossRef

73.

Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006;8:1997–2006.PubMedCrossRef

74.

Raynaud F, Marcilhac A. Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease. FEBS J. 2006;273:3437–43.PubMedCrossRef

75.

Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps. Apoptosis. 2009;14:478–500.PubMedCrossRef

76.

Vicencio JM, Lavandero S, Szabadkai G. Ca2+, autophagy and protein degradation: thrown off balance in neurodegenerative disease. Cell Calcium. 2010;47:112–21.PubMedCrossRef

77.

Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC. Increased M-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience. 1996;73:979–87.PubMedCrossRef

78.

Alvira D, Ferrer I, Gutierrez-Cuesta J, et al. Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord. 2008;14:309–13.PubMedCrossRef

79.

Dufty BM, Warner LR, Hou ST, et al. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol. 2007;170:1725–38.PubMedCrossRef

80.

Gafni J, Ellerby LM. Calpain activation in Huntington's disease. J Neurosci. 2002;22:4842–9.PubMed

81.

Kim YJ, Yi Y, Sapp E, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci U S A. 2001;98:12784–9.PubMedCrossRef

82.

Wellington CL, Ellerby LM, Gutekunst CA, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci. 2002;22:7862–72.PubMed

83.

Gafni J, Hermel E, Young JE, et al. Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of calpain/caspase fragments in the nucleus. J Biol Chem. 2004;279:20211–20.PubMedCrossRef

84.

Nilsson E, Alafuzoff I, Blennow K, et al. Calpain and calpastatin in normal and Alzheimer-degenerated human brain tissue. Neurobiol Aging. 1990;11:425–31.PubMedCrossRef

85.

Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A. 1993;90:2628–32.PubMedCrossRef

86.

•• Higuchi M, Iwata N, Matsuba Y, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J. 2011; doi:10.1096/fj.11-187740. This study reports that cerebrospinal fluid from patients with AD contained a higher level of calpain-cleaved spectrin than that of control patients.

87.

Rohn TT, Head E. Caspase activation in Alzheimer's disease: early to rise and late to bed. Rev Neurosci. 2008;19:383–93.PubMed

88.

Garg S, Timm T, Mandelkow EM, et al. Cleavage of Tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol Aging. 2011;32:1–14.PubMedCrossRef

89.

Gaczyńska M. Changes in proteolytic susceptibility of human erythrocyte membrane proteins during red blood cell aging. Cytobios. 1992;72:197–200.PubMed

90.

Lee A, Morrow JS, Fowler VM. Caspase remodeling of the spectrin membrane skeleton during lens development and aging. J Biol Chem. 2001;276:20735–42.PubMedCrossRef

91.

Bahr BA, Vanderklish PW, Ha LT, et al. Spectrin breakdown products increase with age in telencephalon of mouse brain. Neurosci Lett. 1991;131:237–40.PubMedCrossRef

92.

Bernath E, Kupina N, Liu MC, et al. Elevation of cytoskeletal protein breakdown in aged Wistar rat brain. Neurobiol Aging. 2006;27:624–32.PubMedCrossRef

93.

Ayala-Grosso C, Tam J, Roy S, et al. Caspase-3 cleaved spectrin colocalizes with neurofilament-immunoreactive neurons in Alzheimer's disease. Neuroscience. 2006;141:863–74.PubMedCrossRef

94.

•• Liang B, Duan BY, Zhou XP, et al. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem. 2010;285:27737–44. This study shows elevation of calpain-mediated SBDPs in the brain in a transgenic model of AD, and attenuation of amyloid plaque pathogenesis and tau phosphorylation by in vivo inhibition of calpain activity.PubMedCrossRef

95.

Zhang XM, Cai Y, Xiong K, et al. Beta-secretase-1 elevation in transgenic mouse models of Alzheimer's disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. Eur J Neurosci. 2009;30:2271–83.PubMedCrossRef

Titel: Spectrin Breakdown Products (SBDPs) as Potential Biomarkers for Neurodegenerative Diseases
verfasst von: Xiao-Xin Yan
Andreas Jeromin
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Current Geriatrics Reports / Ausgabe 2/2012
Elektronische ISSN: 2196-7865
DOI: https://doi.org/10.1007/s13670-012-0009-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Biomarkers in Mood Disorders Among the Elderly: Can They Contribute to Diagnosis and Prognosis?

Erratum to: Animal Models of Alzheimer’s Disease: Utilization of Transgenic Alzheimer’s Disease Models in Studies of Amyloid Beta Clearance

Neuropsychological Parameters as Potential Biomarkers for Alzheimer’s Disease

Biomarkers of Cognitive Training Effects in Aging

Use of Telomere Length as a Biomarker for Aging and Age-Related Disease